When Gary Glick, Ph.D. left the CEO post at IFM Therapeutics, he didn’t know what was next. But he soon found himself on a plane with Loxo Oncology co-founder Keith Flaherty, and they got to talking about how they could “expand the boundaries of targeted oncology.” Scorpion Therapeutics was born.
It’s back-to-school season, and that puts me in the frame of mind to share some of the most important lessons I’ve learned in a long career focusing on one of the most daunting pillars of the biopharma BD world: the negotiation.
By Deanna Petersen, Chief Business Officer of AVROBIO, as part of the From The Trenches feature of LifeSciVC.
The drug industry has funneled billions of dollars into cell therapies over the last several years. But there may be something new on the horizon, and a new Cambridge startup is angling to be at the forefront.
I have many fond memories of St Patrick’s Day—most of them involve marching in the parade with a plastic bag and a few extra layers under my girl scout uniform. When you grow up in Ireland, cold rain is not grounds to cancel anything.
By Aoife Brennan, CEO of Synlogic Therapeutics, as part of the From The Trenches feature of LifeSciVC
SPACs are all the rage today. With the IPO market booming and public investors seeking better returns, blank check companies called “Special Purpose Acquisition Companies” (SPACs) have been fueling up their tanks and chasing down their merger targets. New ones are getting announced every day, including in biotech: so much so that serial entrepreneur Mike Gilman tweeted that “it’s raining SPACs” – a sentiment that captures the frenzied downpour of activity.